Bacillus calmette-guerin substrain connaught live antigen
Identification
- Name
- Bacillus calmette-guerin substrain connaught live antigen
- Accession Number
- DB10804
- Description
Bacillus calmette-guerin substrain connaught live antigen is intravesically administered for the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder and for the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR). The solution contains live, attenuated strain of Mycobacterium bovis. It is prepared from the Connaught strain of Bacillus Calmette and Guérin.
- Type
- Biotech
- Groups
- Approved, Investigational
- Biologic Classification
- Vaccines
Attenuated - Synonyms
- BCG, Live, Connaught Strain
Pharmacology
- Indication
Indicated for intravesical use in the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder and for the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR).
- Associated Conditions
- Associated Therapies
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Unlock Additional DataAbacavir The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Abacavir. Abatacept The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Abatacept. Acyclovir The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Acyclovir. Adalimumab The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Adalimumab. Adefovir dipivoxil The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Adefovir dipivoxil. Aldesleukin The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Aldesleukin. Alefacept The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Alefacept. Alemtuzumab The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Alemtuzumab. Altretamine The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Altretamine. Amantadine The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Amantadine. Additional Data Available- Extended DescriptionExtended DescriptionAvailable for Purchase
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more - SeveritySeverityAvailable for Purchase
A severity rating for each drug interaction, from minor to major.
Learn more - Evidence LevelEvidence LevelAvailable for Purchase
A rating for the strength of the evidence supporting each drug interaction.
Learn more - ActionActionAvailable for Purchase
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more
- Food Interactions
- Not Available
Products
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Unlock Additional DataBcg Vaccine (freeze-dried) Powder, for solution Intradermal Sanofi Pasteur Limited 1961-12-31 2015-08-18 Canada Immucyst Powder, for suspension Intravesical Sanofi Pasteur Limited 1990-12-31 2018-01-31 Canada Theracys Injection, powder, lyophilized, for solution 81 mg/3mL Intravesical Sanofi Pasteur Limited 2011-07-22 2017-05-08 US Additional Data Available- Application NumberApplication NumberAvailable for Purchase
A unique ID assigned by the FDA when a product is submitted for approval by the labeller.
Learn more - Product CodeProduct CodeAvailable for Purchase
A governmentally-recognized ID which uniquely identifies the product within its regulatory market.
Learn more
Categories
- Drug Categories
- Classification
- Not classified
Chemical Identifiers
- UNII
- 5H5854UBMZ
- CAS number
- Not Available
References
- General References
- Not Available
- External Links
- AHFS Codes
- 80:12.00 — Vaccines
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Treatment Cancer, Bladder 1 3 Recruiting Prevention Coronavirus Disease 2019 (COVID‑19) / COVID / COVID - 19 1 3 Recruiting Treatment Cancer, Bladder 2
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Powder, for solution Intradermal Powder, for suspension Intravesical Injection, powder, lyophilized, for solution Intravesical 81 mg/3mL - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created on December 01, 2015 13:04 / Updated on January 25, 2021 22:38